Dr-Anik Maitra

Dr-Anik Maitra Health Related information And Treatment

09/06/2025

📌 Topic: Hartmann’s Solution āϏāĻŽā§āĻĒāĻ°ā§āϕ⧇ āĻāĻŦāĻ‚ āĻāϰ āĻŦā§āϝāĻŦāĻšāĻžāϰ āϏāĻŽā§āĻĒāĻ°ā§āϕ⧇ āĻœā§‡āύ⧇ āύāĻŋāύ 👇

🔴 Hartmann’s Solution, āϝāĻž Ringer's Lactate (RL) Solution āύāĻžāĻŽā§‡āĻ“ āĻĒāϰāĻŋāϚāĻŋāϤ, āĻāĻ•āϟāĻŋ Intravenous (IV) fluid āϝāĻž āĻļāϰ⧀āϰ⧇ āϤāϰāϞ āĻ“ āχāϞ⧇āĻ•ā§āĻŸā§āϰ⧋āϞāĻžāχāϟ āĻŦā§āϝāĻžāϞāĻžāĻ¨ā§āϏ āĻŦāϜāĻžā§Ÿ āϰāĻžāĻ–āϤ⧇ āĻŦā§āϝāĻŦāĻšā§ƒāϤ āĻšā§ŸāĨ¤ āĻāϟāĻŋ āϏāĻžāϧāĻžāϰāĻŖāϤ Dehydration, Shock, āϏāĻžāĻ°ā§āϜāĻžāϰāĻŋ āĻĒāϰāĻŦāĻ°ā§āϤ⧀ āĻĢā§āϞ⧁āχāĻĄ āĻŽā§āϝāĻžāύ⧇āϜāĻŽā§‡āĻ¨ā§āϟ, āĻāĻŦāĻ‚ Acidosis āϏāĻ‚āĻļā§‹āϧāύ⧇ āĻŦā§āϝāĻŦāĻšā§ƒāϤ āĻšā§ŸāĨ¤

✅ āĻ—āĻ āύ:

🔸Hartmann’s Solution-āĻ āύāĻŋāĻŽā§āύāϞāĻŋāĻ–āĻŋāϤ āωāĻĒāĻžāĻĻāĻžāύ āĻĨāĻžāϕ⧇:

â–Ēī¸Sodium Chloride (NaCl): 0.60%
â–Ēī¸Potassium Chloride (KCl): 0.04%
â–Ēī¸Calcium Chloride (CaCl₂): 0.027%
â–Ēī¸Sodium Lactate: 0.32%

🔸āχāϞ⧇āĻ•ā§āĻŸā§āϰ⧋āϞāĻžāχāϟ āĻ•āύāϏ⧇āύāĻŸā§āϰ⧇āĻļāύ (Per Liter):

â–Ēī¸Sodium (Naâē): 131 mmol/L
â–Ēī¸Potassium (Kâē): 5 mmol/L
â–Ēī¸Calcium (Ca²âē): 2 mmol/L
â–Ēī¸Chloride (Clâģ): 111 mmol/L
â–Ēī¸Lactate (HCO₃âģ, Bicarbonate Precursor): 29 mmol/L
â–Ēī¸Osmolarity: 273 mOsm/L

✅ āĻŦā§āϝāĻŦāĻšāĻžāϰ:

1. Hypovolemia āĻŦāĻž Fluid Deficit Correction

āϝ⧇āϏāĻŦ āϰ⧋āĻ—ā§€āϰ āĻļāϰ⧀āϰ⧇ āϰāĻ•ā§āϤ āĻŦāĻž āϤāϰāϞ⧇āϰ āϘāĻžāϟāϤāĻŋ āĻšāϝāĻŧ, āϝ⧇āĻŽāύ:

â–Ēī¸Severe dehydration (āĻ…āϤāĻŋāϰāĻŋāĻ•ā§āϤ āĻĄāĻžāϝāĻŧāϰāĻŋāϝāĻŧāĻž āĻŦāĻž āĻŦāĻŽāĻŋāϰ āĻĢāϞ⧇)
â–Ēī¸Hemorrhage (āϰāĻ•ā§āϤāĻĒāĻžāϤ⧇āϰ āĻĢāϞ⧇ āϰāĻ•ā§āϤ⧇āϰ āĻĒāϰāĻŋāĻŽāĻžāĻŖ āĻ•āĻŽā§‡ āϝāĻžāĻ“āϝāĻŧāĻž)
â–Ēī¸Shock condition (low BP, poor perfusion)
āĻāχ āĻ…āĻŦāĻ¸ā§āĻĨāĻžāϝāĻŧ Hartmann’s Solution āĻŦā§āϝāĻŦāĻšāĻžāϰ āĻ•āϰ⧇ āĻļāϰ⧀āϰ⧇ āĻĻā§āϰ⧁āϤ āĻĢā§āϞ⧁āχāĻĄ āĻĒ⧁āύāσāĻ¸ā§āĻĨāĻžāĻĒāύ āĻ•āϰāĻž āĻšāϝāĻŧāĨ¤

2. Burn Management

Burn patients āĻāϰ āĻļāϰ⧀āϰ āĻĨ⧇āϕ⧇ āĻ…āύ⧇āĻ• āĻĒāϰāĻŋāĻŽāĻžāϪ⧇ fluid loss āĻšāϝāĻŧāĨ¤

â–Ēī¸āĻāχ āĻ…āĻŦāĻ¸ā§āĻĨāĻžāϝāĻŧ Hartmann’s solution āĻŦā§āϝāĻŦāĻšā§ƒāϤ āĻšāϝāĻŧ initial resuscitation fluid āĻšāĻŋāϏ⧇āĻŦ⧇āĨ¤
â–Ēī¸āĻāϤ⧇ āĻĨāĻžāĻ•āĻž lactate acidosis āĻ•āĻŽāĻžāϤ⧇ āϏāĻžāĻšāĻžāĻ¯ā§āϝ āĻ•āϰ⧇ āĻāĻŦāĻ‚ electrolytes āĻ­āĻžāϰāϏāĻžāĻŽā§āϝ āϰāĻžāϖ⧇āĨ¤

3. Surgery āĻ“ Post-operative Phase āĻ Fluid Replacement

āĻ…āĻĒāĻžāϰ⧇āĻļāύ⧇āϰ āφāϗ⧇ āĻ“ āĻĒāϰ⧇ āϰ⧋āĻ—ā§€āϰ āĻļāϰ⧀āϰ⧇ āĻĢā§āϞ⧁āχāĻĄ āĻ“ āχāϞ⧇āĻ•āĻŸā§āϰ⧋āϞāĻžāχāϟ āĻŦā§āϝāĻžāϞāĻžāĻ¨ā§āϏ āĻ āĻŋāĻ• āϰāĻžāĻ–āϤ⧇ Hartmann’s Solution āĻŦā§āϝāĻŦāĻšā§ƒāϤ āĻšāϝāĻŧāĨ¤

â–Ēī¸āĻŦāĻŋāĻļ⧇āώ āĻ•āϰ⧇ abdominal āĻ“ orthopedic surgery-āĻāϰ āĻ•ā§āώ⧇āĻ¤ā§āϰ⧇āĨ¤
â–Ēī¸āĻāϟāĻŋ āϰāĻ•ā§āϤ⧇āϰ āĻŽāϤ⧋ composition āĻšāĻ“āϝāĻŧāĻžāϝāĻŧ āĻļāϰ⧀āϰ āϏāĻšāĻœā§‡ āĻ—ā§āϰāĻšāĻŖ āĻ•āϰ⧇āĨ¤

4. Acute Blood Loss āĻŦāĻž Trauma Patient Management

āϝāĻ–āύ āϕ⧋āύ⧋ āϰ⧋āĻ—ā§€āϰ accident āĻŦāĻž injury-āĻāϰ āĻĢāϞ⧇ āĻ…āύ⧇āĻ• āϰāĻ•ā§āϤāĻ•ā§āώāϰāĻŖ āĻšāϝāĻŧ⧇āϛ⧇, āϤāĻ–āύ Hartmann’s āĻĻ⧇āĻ“ā§ŸāĻž āĻšāϝāĻŧ fluid replacement āĻāϰ āϜāĻ¨ā§āϝāĨ¤

â–Ēī¸āĻāϟāĻŋ intravascular volume restore āĻ•āϰ⧇
â–Ēī¸Hypotension āĻ“ organ perfusion āĻ āĻŋāĻ• āϰāĻžāϖ⧇āĨ¤

5. Metabolic Acidosis Correction

Hartmann’s-āĻ āĻĨāĻžāĻ•āĻž lactate āĻļāϰ⧀āϰ⧇ āĻ—āĻŋāϝāĻŧ⧇ bicarbonate-āĻ āϰ⧂āĻĒāĻžāĻ¨ā§āϤāϰāĻŋāϤ āĻšāϝāĻŧ, āϝāĻž mild to moderate metabolic acidosis āĻ āĻŋāĻ• āĻ•āϰāϤ⧇ āϏāĻžāĻšāĻžāĻ¯ā§āϝ āĻ•āϰ⧇āĨ¤
â–Ēī¸āϝ⧇āĻŽāύ: diarrhea-induced acidosis, renal loss of bicarbonate āχāĻ¤ā§āϝāĻžāĻĻāĻŋāĨ¤

6. Obstetric Uses

â–Ēī¸Labor āϚāϞāĻžāĻ•āĻžāϞ⧀āύ āĻŦāĻž C-section āĻāϰ āϏāĻŽāϝāĻŧ fluid āĻĻāĻŋāϤ⧇ Hartmann’s āĻŦā§āϝāĻŦāĻšāĻžāϰ āĻšāϝāĻŧāĨ¤
â–Ēī¸Preeclampsia āĻŦāĻž eclampsia-āϤ⧇ āϏāĻ āĻŋāĻ• fluid balance āĻŦāϜāĻžā§Ÿ āϰāĻžāĻ–āϤ⧇ āĻāϟāĻŋ āĻĻ⧇āĻ“ā§ŸāĻž āĻšā§ŸāĨ¤

7. Pancreatitis

Acute pancreatitis āϰ⧋āĻ—ā§€āϰ fluid resuscitation-āĻāϰ āϜāĻ¨ā§āϝ Hartmann’s āĻŦā§āϝāĻŦāĻšāĻžāϰ āĻ•āϰāĻž āĻšā§ŸāĨ¤
â–Ēī¸āĻ•āĻžāϰāĻŖ āĻāϤ⧇ āĻĨāĻžāĻ•āĻž lactate āĻāĻŦāĻ‚ balanced electrolytes āϰ⧋āĻ—ā§€āϕ⧇ metabolically support āĻ•āϰ⧇āĨ¤

8. Sepsis āĻ“ Septic Shock

āϏ⧇āĻĒā§āϟāĻŋāĻ• āĻļāϕ⧇ āĻ…āύ⧇āĻ• fluid loss āĻ“ vasodilation āĻšā§ŸāĨ¤
â–Ēī¸Hartmann’s āĻĻāĻŋā§Ÿā§‡ initial fluid resuscitation āĻ•āϰāĻž āĻšā§Ÿ, āϝāĻžāϤ⧇ perfusion restore āĻšā§Ÿ āĻāĻŦāĻ‚ hypotension āĻ•āĻŽā§‡āĨ¤

9. Trauma Patient āĻāϰ Pre-hospital Management

â–Ēī¸Ambulance āĻŦāĻž emergency setting-āĻ Hartmann’s āĻĻ⧇āĻ“ā§ŸāĻž āĻšā§Ÿ initial stabilization āĻāϰ āϜāĻ¨ā§āϝāĨ¤

✅ āĻĒā§āϰāϤāĻŋāĻ•ā§āϰāĻŋ⧟āĻž āĻ“ āϏāĻžāĻŦāϧāĻžāύāϤāĻž:

â–Ēī¸Hyperkalemia: āϝāĻĻāĻŋ āϰāĻ•ā§āϤ⧇ potassium āĻŦ⧇āĻļāĻŋ āĻĨāĻžāϕ⧇, āϤāĻžāĻšāϞ⧇ Hartmann’s solution āĻŦā§āϝāĻŦāĻšāĻžāϰ āĻ•āϰāĻž āύāĻŋāϰāĻžāĻĒāĻĻ āύ⧟āĨ¤
â–Ēī¸Renal Failure āĻĨāĻžāĻ•āϞ⧇ āĻ•āĻŋāĻĄāύāĻŋ āĻĢāĻžāĻ‚āĻļāύ āĻĒāĻ°ā§āϝāĻŦ⧇āĻ•ā§āώāĻŖ āĻ•āϰāϤ⧇ āĻšāĻŦ⧇āĨ¤
â–Ēī¸Lactic Acidosis āĻĨāĻžāĻ•āĻž āϰ⧋āĻ—ā§€āĻĻ⧇āϰ āĻ•ā§āώ⧇āĻ¤ā§āϰ⧇ āϏāϤāĻ°ā§āĻ•āϤāĻž āĻĒā§āĻ°ā§Ÿā§‹āϜāύāĨ¤
â–Ēī¸āĻ•āĻžāĻ°ā§āĻĄāĻŋ⧟āĻžāĻ• āĻŦāĻž āϞāĻŋāĻ­āĻžāϰ āĻĄāĻŋāϜāĻŋāϜ āĻĨāĻžāĻ•āϞ⧇ āĻ“āĻ­āĻžāϰāϞ⧋āĻĄ āĻšāϤ⧇ āĻĒāĻžāϰ⧇, āϤāĻžāχ āϏāĻžāĻŦāϧāĻžāύāϤāĻž āĻĻāϰāĻ•āĻžāϰāĨ¤

06/06/2025

Rabies Vaccine āύāĻŋāϝāĻŧ⧇ āϜāĻžāύāĻž āĻ…āϜāĻžāύāĻž
🐕 āϕ⧁āϕ⧁āϰ āĻ•āĻžāĻŽā§œ āĻŽāĻžāύ⧇āχ āĻļ⧁āϧ⧁āĻŽāĻžāĻ¤ā§āϰ āĻāĻ•āϟāĻž āĻŦā§āϝāĻĨāĻž āύāĻž — āĻšāϤ⧇ āĻĒāĻžāϰ⧇ āĻāϕ⧇ āĻāϕ⧇ āĻŽā§ƒāĻ¤ā§āϝ⧁āϰ āϏāĻŋāρ⧜āĻŋāĻ“!
āϤāĻžāχ āĻ•āĻžāĻŽā§œā§‡āϰ āĻĒāϰ "āĻ­āĻžāϞ⧋ āφāĻ›āĻŋ" āĻŦāϞāĻžāϰ āφāϗ⧇ āύāĻŋāĻļā§āϚāĻŋāϤ āĻšā§Ÿā§‡ āύāĻŋāύ, āφāĻĒāύāĻŋ āφāĻĻ⧌ āϏ⧁āϰāĻ•ā§āώāĻŋāϤ āϤ⧋?

🔴 āϕ⧋āύ āĻ•āĻžāĻŽā§œ āĻ•āϤāϟāĻž āϭ⧟āĻ‚āĻ•āϰ?
āϚāĻŋāύ⧇ āύāĻŋāύ ‘Category III Bite’

āϝāĻĻāĻŋ—

✅ āĻ•āĻžāĻŽā§œā§‡āϰ āĻĻāĻžāĻ— āĻĨ⧇āϕ⧇ āϰāĻ•ā§āϤ āĻŦ⧇āϰ āĻšā§Ÿ
✅ āϚāĻžāĻŽā§œāĻžāϰ āĻ—āĻ­ā§€āϰ⧇ āĻ—āĻŋā§Ÿā§‡ āĻāĻ•āĻžāϧāĻŋāĻ• āĻ•āĻžāĻŽā§œ āϞāĻžāϗ⧇
✅ āĻŽā§āĻ–, āĻŽāĻžāĻĨāĻž, āφāϙ⧁āϞ, āĻŦāĻž āϝ⧌āύāĻžāĻ™ā§āϗ⧇āϰ āĻŽāϤ⧋ āĻ¸ā§āĻĒāĻ°ā§āĻļāĻ•āĻžāϤāϰ āĻ¸ā§āĻĨāĻžāύ⧇ āĻ•āĻžāĻŽā§œ āϞāĻžāϗ⧇
✅ āĻ…āĻĨāĻŦāĻž āĻ•ā§āώāϤāϚāĻŋāĻšā§āύ⧇ āϕ⧁āϕ⧁āϰ āĻŦāĻž āĻŦāĻŋ⧜āĻžāϞ āĻšā§‡āĻŸā§‡ āĻĻā§‡ā§Ÿ

👉 āϤāĻžāĻšāϞ⧇ āĻāϟāĻŋ Category III Bite — āϰ⧇āĻŦāĻŋāϏ āĻ­āĻžāχāϰāĻžāϏ āĻĸā§‹āĻ•āĻžāϰ āϏāĻŦāĻšā§‡ā§Ÿā§‡ āĻŦāĻŋāĻĒāĻœā§āϜāύāĻ• āĻĻāϰāϜāĻž!

🛑 āĻāχ āĻ•ā§āϝāĻžāϟāĻžāĻ—āϰāĻŋāϤ⧇ āĻļ⧁āϧ⧁ āĻ­ā§āϝāĻžāĻ•āϏāĻŋāύ āĻĻāĻŋāϞ⧇ āĻšā§Ÿ āύāĻž — RIG (Rabies Immunoglobulin) āĻ“ āĻĻāĻŋāϤ⧇ āĻšā§Ÿ āĻāĻ•āϏāĻžāĻĨ⧇, āϝ⧇āύ āĻ­āĻžāχāϰāĻžāϏ āĻļāϰ⧀āϰ⧇ āĻĸā§‹āĻ•āĻžāϰ āφāϗ⧇āχ āĻļ⧇āώ āĻšā§Ÿā§‡ āϝāĻžā§Ÿ!

💉 āĻ­ā§āϝāĻžāĻ•āϏāĻŋāύ⧇āĻļāύ āĻ—āĻžāχāĻĄāϞāĻžāχāύ – āĻ•āĻŦ⧇ āϕ⧀āĻ­āĻžāĻŦ⧇ āύāĻŋāϤ⧇ āĻšāĻŦ⧇?
(āϏ⧂āĻ¤ā§āϰ: National guideline)

🔹 Post Exposure Prophylaxis (PEP) — āĻ•āĻžāĻŽā§œā§‡āϰ āĻĒāϰ āϰ⧋āĻ—ā§€ āφāϏāϞ⧇
📌 IM Route (Essen Schedule):
(āĻŽāĻžāύ⧇ āĻŽāĻžāĻ‚āϏ⧇ āχāύāĻœā§‡āĻ•āĻļāύ)
➤ ā§§āϟāĻŋ āĻ­āĻžā§ŸāĻžāϞ āĻ•āϰ⧇ āύāĻŋāϤ⧇ āĻšāĻŦ⧇ D0, D3, D7, D14
āĻ…āĻĨāĻŦāĻž,
📌 IDRV Route (Intradermal):
(āĻŽāĻžāύ⧇ āϚāĻžāĻŽāĻĄāĻŧāĻžāϝāĻŧ āχāύāĻœā§‡āĻ•āĻļāύ)

➤ ā§Ļ.ā§§ ml × ⧍ āĻŦāĻžāϰ āĻĻāĻŋāϤ⧇ āĻšāĻŦ⧇ D0, D3, D7 (āϏāĻžāχāϟ: āĻĻ⧁āχ āĻĄā§‡āϞāĻŸā§Ÿā§‡āĻĄ āĻ…āĻžā§āϚāϞ)
✅ Category III Bite āĻšāϞ⧇ āĻ…āĻŦāĻļā§āϝāχ RIG āĻĻāĻŋāϤ⧇ āĻšāĻŦ⧇

(Day 0 āĻ…āĻ°ā§āĻĨā§āϝāĻžā§Ž āĻ•āĻžāĻŽāĻĄāĻŧ⧇āϰ āĻĻāĻŋāύ, D3 āĻ…āĻ°ā§āĻĨāĻžā§Ž āĻ•āĻžāĻŽāĻĄāĻŧ⧇āϰ āĻĒāϰ āϤ⧃āϤ⧀āϝāĻŧ āĻĻāĻŋāύ)

🔹 Pre-Exposure Prophylaxis (PrEP) — āφāϗ⧇āĻ­āĻžāϗ⧇āχ āϏ⧁āϰāĻ•ā§āώāĻž āύāĻŋāϤ⧇ āϚāĻžāχāϞ⧇
📌 IM Route:
➤ ā§§āϟāĻŋ āĻ­āĻžā§ŸāĻžāϞ āĻ•āϰ⧇ D0 āĻ“ D7
āĻ…āĻĨāĻŦāĻž,
📌 IDRV Route:
➤ ā§Ļ.ā§§ ml × ⧍ āĻŦāĻžāϰ, D0 āĻ“ D7 (āĻĄā§‡āϞāĻŸā§Ÿā§‡āĻĄ āĻ…āĻžā§āϚāϞ⧇)

🔹 Re-Exposure Prophylaxis (PEP) — āĻĒā§‚āĻ°ā§āĻŦ⧇ āϟāĻŋāĻ•āĻž āĻĻ⧇āĻ“ā§ŸāĻž āĻĨāĻžāĻ•āϞ⧇
📌 IM Route:
➤ ā§§āϟāĻŋ āĻ­āĻžā§ŸāĻžāϞ āĻ•āϰ⧇ D0 āĻ“ D3
āĻ…āĻĨāĻŦāĻž,

📌 IDRV Route:
➤ ā§Ļ.ā§§ ml × ā§§ āĻŦāĻžāϰ āĻ•āϰ⧇ D0 āĻ“ D3

🕒 āĻ­ā§āϝāĻžāĻ•āϏāĻŋāύ āύāĻŋāϤ⧇ ā§§â€“ā§¨ āĻĻāĻŋāύ āĻĻ⧇āϰāĻŋ āĻšāϞ⧇ āϕ⧀ āĻšāĻŦ⧇?

👉 Rabies vaccine-āĻāϰ āĻļāĻŋāĻĄāĻŋāωāϞ āĻāĻ•āϟ⧁ āĻĻ⧇āϰāĻŋāϤ⧇ āύāĻŋāϞ⧇ āĻ­ā§āϝāĻžāĻ•āϏāĻŋāύ āĻŦāĻžāϤāĻŋāϞ āĻšā§Ÿ āύāĻžāĨ¤
āĻŦāĻŋāĻļā§āĻŦ āĻ¸ā§āĻŦāĻžāĻ¸ā§āĻĨā§āϝ āϏāĻ‚āĻ¸ā§āĻĨāĻž (WHO) āĻāĻŦāĻ‚ āĻŦāĻžāĻ‚āϞāĻžāĻĻ⧇āĻļ āĻ¨ā§āϝāĻžāĻļāύāĻžāϞ āĻ—āĻžāχāĻĄāϞāĻžāχāύ⧇āϰ āύāĻŋāĻ°ā§āĻĻ⧇āĻļāύāĻž āĻ…āύ⧁āϝāĻžā§Ÿā§€, āφāĻĒāύāĻŋ—

✅ āϝ⧇ āĻĻāĻŋāύ āĻŽāĻŋāϏ āĻ•āϰ⧇āϛ⧇āύ, āϤāĻžāϰ āĻĒāϰāĻŦāĻ°ā§āϤ⧀ āĻĻāĻŋāύ⧇ āĻ—āĻŋā§Ÿā§‡ āϏ⧇āχ āĻĄā§‹āϜāϟāĻŋ āύāĻŋā§Ÿā§‡ āύāĻŋāϤ⧇ āĻĒāĻžāϰ⧇āύ
✅ āĻĒāϰāĻŦāĻ°ā§āϤ⧀ āĻĄā§‹āϜāϗ⧁āϞ⧋ āφāĻŦāĻžāϰ āφāϗ⧇āϰ āĻļāĻŋāĻĄāĻŋāωāϞ āϧāϰ⧇āχ āĻĻāĻŋāύ (reset āĻ•āϰāĻž āϞāĻžāĻ—āĻŦ⧇ āύāĻž)

📌 āωāĻĻāĻžāĻšāϰāĻŖ:

āφāĻĒāύāĻŋ D3 āĻāϰ āĻ­ā§āϝāĻžāĻ•āϏāĻŋāύ D5 āϤāĻžāϰāĻŋāϖ⧇ āύāĻŋāϞ⧇āύ
→ āĻāϰ āĻĒāϰ⧇āĻ“ D7, D14 āφāϗ⧇āϰ āĻļāĻŋāĻĄāĻŋāωāϞ āĻŽāϤ⧋āχ āĻĻ⧇āĻŦ⧇āύ

🔴 āĻ•āĻ–āύ āĻ­ā§āϝāĻžāĻ•āϏāĻŋāύ āϏāĻŋāϰāĻŋāϜ āϰāĻŋāĻ¸ā§āϟāĻžāĻ°ā§āϟ āĻ•āϰāϤ⧇ āĻšā§Ÿ?
➤ āϏāĻžāϧāĻžāϰāĻŖāϤ, ā§Ģâ€“ā§­ āĻĻāĻŋāύ⧇āϰ āĻŦ⧇āĻļāĻŋ āĻĻ⧇āϰāĻŋ āĻšāϞ⧇, āĻ…āĻĨāĻŦāĻž āĻĒ⧁āϰ⧋ āϏāĻŋāϰāĻŋāϜ āĻ…āύ⧇āĻ•āĻ–āĻžāύāĻŋ āĻŽāĻŋāϏ āĻ•āϰāϞ⧇, āϤāĻ–āύ āϚāĻŋāĻ•āĻŋā§ŽāϏāĻ• āύāϤ⧁āύ āĻ•āϰ⧇ āĻļāĻŋāĻĄāĻŋāωāϞ āĻļ⧁āϰ⧁ āĻ•āϰāϤ⧇ āĻŦāϞāϤ⧇ āĻĒāĻžāϰ⧇āύ
➤ āχāĻŽāĻŋāωāύ⧋āĻ•āĻŽā§āĻĒā§āϰ⧋āĻŽāĻžāχāϜāĻĄ āϰ⧋āĻ—ā§€ āĻšāϞ⧇, āĻĻ⧇āϰāĻŋ āĻ•āϰāϞ⧇āĻ“ āĻŦāĻžā§œāϤāĻŋ āϏāϤāĻ°ā§āĻ•āϤāĻž āύāĻŋāϤ⧇ āĻšā§Ÿ

💡 āĻŦā§āϝāĻŦāĻšāĻžāϰāĻŋāĻ• āϟāĻŋāĻĒāϏ:

āϟāĻŋāĻ•āĻž Miss āĻšā§Ÿā§‡ āϗ⧇āϞ⧇ āĻĻ⧇āϰāĻŋ āύāĻž āĻ•āϰ⧇ āϝāϤ āĻĻā§āϰ⧁āϤ āϏāĻŽā§āĻ­āĻŦ āύ⧇āĻ“ā§ŸāĻž āĻļ⧁āϰ⧁ āĻ•āϰ⧁āύ

āĻĒā§āϰāϤāĻŋāϟāĻŋ āĻĄā§‹āĻœā§‡āϰ āϤāĻžāϰāĻŋāĻ– āύ⧋āϟ āĻ•āϰ⧇ āϰāĻžāϖ⧁āύ

āĻšāĻžāϏāĻĒāĻžāϤāĻžāϞ⧇ āĻ—āĻŋā§Ÿā§‡ āϚāĻŋāĻ•āĻŋā§ŽāϏāϕ⧇āϰ āĻĒāϰāĻžāĻŽāĻ°ā§āĻļ āύāĻŋāύ — āωāύāĻŋ āĻŦ⧁āĻā§‡ āĻŦāϞ⧇ āĻĻ⧇āĻŦ⧇āύ āφāĻĒāύāĻžāϕ⧇ āϕ⧀āĻ­āĻžāĻŦ⧇ āϚāĻžāϞāĻžāϤ⧇ āĻšāĻŦ⧇āĨ¤

đŸ§Ē IM āφāϰ ID āϰ⧁āϟ āĻŽāĻŋāĻļāĻŋā§Ÿā§‡ āĻĻ⧇āĻ“ā§ŸāĻž āϝāĻžāĻŦ⧇ āĻ•āĻŋ?

✅ āύāĻž, WHO āĻāĻŦāĻ‚ āĻŦāĻžāĻ‚āϞāĻžāĻĻ⧇āĻļ National Rabies Prevention Guideline āĻ…āύ⧁āϝāĻžā§Ÿā§€ āĻāĻ•āĻŦāĻžāϰ āϝ⧇āχ āϰ⧁āĻŸā§‡ āĻļ⧁āϰ⧁ āĻ•āϰāĻŦ⧇āύ, āĻĒ⧁āϰ⧋ āϏāĻŋāϰāĻŋāϜ āĻ“āχ āϰ⧁āĻŸā§‡āχ āĻļ⧇āώ āĻ•āϰāϤ⧇ āĻšāĻŦ⧇āĨ¤

đŸšĢ āĻ…āĻ°ā§āĻĨāĻžā§Ž IM āĻĻāĻŋā§Ÿā§‡ āĻļ⧁āϰ⧁ āĻ•āϰāϞ⧇ āĻĒāϰ⧇āϰāϗ⧁āϞ⧋āĻ“ IM-āχ āĻĻāĻŋāϤ⧇ āĻšāĻŦ⧇,
āφāϰ ID āĻĻāĻŋā§Ÿā§‡ āĻļ⧁āϰ⧁ āĻ•āϰāϞ⧇ āĻŦāĻžāĻ•āĻŋ āϏāĻŦ āĻĄā§‹āϜāĻ“ ID-āϤ⧇āχ āĻĻāĻŋāϤ⧇ āĻšāĻŦ⧇āĨ¤

đŸŠē āϰ⧋āĻ—ā§€ āϝāĻĻāĻŋ āĻĒā§āϰāĻĨāĻŽ āĻĄā§‹āϜ IM āύāĻŋā§Ÿā§‡ āĻĢ⧇āϞ⧇, āĻāϰāĻĒāϰ ID āύāĻŋāϤ⧇ āϚāĻžā§Ÿ?

āϤāĻžāĻšāϞ⧇ āĻ•āϰāĻŖā§€ā§Ÿ: 👉 āĻĒā§āϰāĻĨāĻŽ āĻĄā§‹āϜ āĻŦāĻžāϤāĻŋāϞ āĻŦāϞ⧇ āϧāϰ⧇ āύāĻŋāϤ⧇ āĻšāĻŦ⧇
👉 āĻāϰāĻĒāϰ āĻĨ⧇āϕ⧇ āύāϤ⧁āύ āĻ•āϰ⧇ ID āϰ⧁āĻŸā§‡ Day 0 āĻĨ⧇āϕ⧇ āĻļ⧁āϰ⧁ āĻ•āϰāϤ⧇ āĻšāĻŦ⧇
👉 āĻ…āĻ°ā§āĻĨāĻžā§Ž IM → ID āĻŽāĻŋāĻļāĻŋā§Ÿā§‡ āϚāĻžāϞāĻžāύ⧋ āϝāĻžāĻŦ⧇ āύāĻž

💡 āĻāĻŽāύāĻ•āĻŋ āωāĻ˛ā§āĻŸā§‹āϟāĻž āĻšāϞ⧇āĻ“ — ID āĻĻāĻŋā§Ÿā§‡ āĻļ⧁āϰ⧁ āĻ•āϰ⧇ āĻĒāϰ⧇ IM āĻĻāĻŋāϞ⧇ — āĻāϟāĻžāĻ“ āϭ⧁āϞāĨ¤ āĻ“āχ āĻ•ā§āώ⧇āĻ¤ā§āϰ⧇āĻ“ āφāĻŦāĻžāϰ āĻļ⧁āϰ⧁ āĻ•āϰāϤ⧇ āĻšā§ŸāĨ¤

📌 āϕ⧇āύ āĻāϤ āĻ•ā§œāĻžāĻ•ā§œāĻŋ?

āĻ•āĻžāϰāĻŖ IM āĻ“ ID āϰ⧁āĻŸā§‡ dose, immunogenicity, antibody response āϟāĻžāχ āφāϞāĻžāĻĻāĻž

ID āϤ⧇ ā§Ļ.ā§§ mL āĻ•āϰ⧇ ⧍āϟāĻŋ āχāύāĻœā§‡āĻ•āĻļāύ āϞāĻžāϗ⧇, āφāϰ IM āĻ āϞāĻžāϗ⧇ āĻĒ⧁āϰ⧋ ā§§ vial

āϤāĻžāχ āĻŽāĻŋāĻ•ā§āϏ āĻ•āϰāϞ⧇ protection incomplete āĻšā§Ÿā§‡ āϝ⧇āϤ⧇ āĻĒāĻžāϰ⧇ — āϝ⧇āϟāĻž Rabies āĻāϰ āĻŽāϤ āϭ⧟āĻ‚āĻ•āϰ āϰ⧋āϗ⧇ āϚāϰāĻŽ āĻŦāĻŋāĻĒāĻœā§āϜāύāĻ•

✅ āϏ⧋āϜāĻž āĻŽāύ⧇ āϰāĻžāĻ–āĻžāϰ āϟāĻŋāĻĒāϏ:

đŸ—“ī¸ āϝ⧇āĻ­āĻžāĻŦ⧇ āĻļ⧁āϰ⧁, āϏ⧇āĻ­āĻžāĻŦ⧇āχ āĻļ⧇āώ
🔁 āϰ⧁āϟ āĻŦāĻĻāϞāĻžāϤ⧇ āϚāĻžāχāϞ⧇ — āĻļ⧁āϰ⧁ āĻ•āϰāϤ⧇ āĻšāĻŦ⧇ āύāϤ⧁āύ āĻ•āϰ⧇ Day 0 āĻĨ⧇āϕ⧇

04/06/2025

Clubbing of nails is associated with various conditions, which can be remembered using the mnemonic C-L-U-B-B-I-N-G:

C – Cyanotic heart disease (e.g., congenital heart diseases like Tetralogy of Fallot)

L – Lung diseases (e.g., lung cancer, bronchiectasis, lung abscess, cystic fibrosis, interstitial lung disease)

U – Ulcerative colitis (and other inflammatory bowel diseases)

B – Biliary cirrhosis (and other chronic liver diseases)

B – Bronchogenic carcinoma (primary lung cancer)

I – Infective endocarditis

N – Neurogenic tumors (rare cause)

G – Gastrointestinal diseases (e.g., Crohn's disease, malabsorption syndromes, esophageal cancer)

Clubbing is characterized by increased nail curvature, loss of the normal Lovibond angle (

18/05/2025

📌 Topic: āĻ¸ā§āϝāĻžāϞāĻžāχāύ⧇āϰ āϘāĻ¨ā§āϟāĻž, āĻĄā§āϰāĻĒ, āĻŽāĻžāχāĻ•ā§āϰ⧋āĻĄā§āϰāĻĒ āϏāĻšāĻœā§‡ āĻŦ⧇āϰ āĻ•āϰāĻž āϏ⧂āĻ¤ā§āϰ āϏāĻŽā§‚āĻš 👇 (āϖ⧁āĻŦāχ āϗ⧁āϰ⧁āĻ¤ā§āĻŦāĻĒā§‚āĻ°ā§āĻŖ, Timeline āĻ āϰ⧇āϖ⧇ āĻĻāĻŋāύ)

1. āϘāĻ¨ā§āϟāĻž āĻŦ⧇āϰ āĻ•āϰāĻžāϰ āϏ⧂āĻ¤ā§āϰ :

✅ Hours = Totall volume Ãˇ Drops x 4

For Example :
â–Ēī¸1000 ml āĻ¸ā§āϝāĻžāϞāĻžāχāύ 30 Drops āĻ•āϰ⧇ āĻĻāĻŋāϞ⧇ āĻļ⧇āώ āĻšāϤ⧇ āĻ•āϤ āϏāĻŽā§Ÿ āϞāĻžāĻ—āĻŦ⧇ ?

👉 āϏ⧂āĻ¤ā§āϰ: Totall Volume Ãˇ Drops × 4

= 1000ml Ãˇ 30×4
= 1000ml Ãˇ 120
= 8 hours

âœ”ī¸ āύ⧋āϟ: āωāĻĒāϰ⧇ 1000ml āĻšāϞ⧋ Totall Volume, 30 Drops āϝāĻž āĻĒā§āϰāĻļā§āύ⧇ āĻĻā§‡ā§ŸāĻž āφāϛ⧇āĨ¤ āφāϰ 4 āĻšāϞ⧋ āϏ⧂āĻ¤ā§āϰ⧇āϰāĨ¤

2. āĻĄā§āϰāĻĒ āĻŦ⧇āϰ āĻ•āϰāĻžāϰ āϏ⧂āĻ¤ā§āϰ:

✅ Drops = Totall volume Ãˇ Hours × 4

For Example:
â–Ēī¸1000ml āĻ¸ā§āϝāĻžāϞāĻžāχāύ 8 āϘāĻ¨ā§āϟāĻžā§Ÿ āĻļ⧇āώ āĻ•āϰāϤ⧇ āĻ•āϤ āĻĄā§āϰāĻĒ⧇ āĻĻāĻŋāϤ⧇ āĻšāĻŦ⧇ ?

👉 āϏ⧂āĻ¤ā§āϰ: Totall Volume Ãˇ Hours × 4

= 1000 ml Ãˇ 8×4
= 1000 ml Ãˇ 32
= 30 Drops

âœ”ī¸ āύ⧋āϟ: āωāĻĒāϰ⧇ 1000ml āĻšāϞ⧋ Totall Volume, 8 āϘāĻ¨ā§āϟāĻž āϝāĻž āĻĒā§āϰāĻļā§āύ⧇ āĻĻā§‡ā§ŸāĻž āφāϛ⧇āĨ¤ āφāϰ 4 āĻšāϞ⧋ āϏ⧂āĻ¤ā§āϰ⧇āϰāĨ¤

3. Microdrops āĻŦ⧇āϰ āĻ•āϰāĻžāϰ āϏ⧂āĻ¤ā§āϰ āĻšāϞ⧋ āĻĄā§āϰāĻĒ āĻŦ⧇āϰ āĻ•āϰ⧇ āϏāĻžāĻĨ⧇ 4 āĻĻāĻŋā§Ÿā§‡ āϗ⧁āύ āĻ•āϰāĻžāĨ¤

✅ Special Note:
â–Ēī¸āĻāĻ–āĻžāύ⧇ āϏ⧂āĻ¤ā§āϰ⧇āϰ 4 āϤāĻ–āύāχ āĻšāĻŦ⧇, āϝāĻ–āύ Drop factor 15 āĻšāĻŦ⧇ 😊
â–Ēī¸Drop factor āĻŽāĻžāύ⧇ 15 drop = 1 ml
â–Ēī¸āĻĒā§āϰāĻļā§āύ⧇ Drop factor 20 āωāĻ˛ā§āϞ⧇āĻ– āĻ•āϰāϞ⧇ āϏ⧂āĻ¤ā§āϰ⧇ 4 āĻāϰ āϜāĻžā§ŸāĻ—āĻžā§Ÿ (60 Ãˇ 20) = 3 āĻšāĻŦ⧇ 😊

17/05/2025

🧒💊 āĻļāĻŋāĻļ⧁āϰ āĻ…ā§āϝāĻžāĻ¨ā§āϟāĻŋāĻŦāĻžā§Ÿā§‹āϟāĻŋāĻ• āĻĄā§‹āϜ āĻļ⧇āĻ–āĻž āĻāĻ–āύ āφāϰāĻ“ āϏāĻšāϜ!

🧠 āĻāĻ•āϜāύ ⧧⧍ āϕ⧇āϜāĻŋ āĻŦāĻžāĻšā§āϚāĻžāϕ⧇ āωāĻĻāĻžāĻšāϰāĻŖ āϧāϰ⧇ āϏāĻŦ āĻĄā§‹āϜ āĻĻ⧇āĻ“ā§ŸāĻž āĻšā§Ÿā§‡āϛ⧇
đŸ“Ļ āĻĒā§āϰāϤāĻŋāϟāĻŋ āĻ—ā§āϰ⧁āĻĒ⧇ popular āĻāĻ•āϟāĻŋ āĻ•āϰ⧇ āĻŦā§āĻ°ā§āϝāĻžāĻ¨ā§āĻĄ name āĻāĻĄ āĻ•āϰāĻž āĻšā§Ÿā§‡āϛ⧇ — āĻŽāύ⧇ āϰāĻžāĻ–āĻž āĻāĻ•āĻĻāĻŽ āϏāĻšāϜ!

⏱ āϏāĻŽā§Ÿ āĻŦāĻžāρāϚāĻžāύ, āĻĻā§āϰ⧁āϤ āĻŽāύ⧇ āϰāĻžāϖ⧁āύ!


đŸ§Ŧ 1st Generation – Cephradine
Brand: Lebac P/D
💉 Formulation: 125 mg / 1.2 ml
🧒 Dose: 14 mg/kg/dose — TDS (3 times/day)
⚡ Shortcut: Weight × 2 drops = 12 × 2 = 24 drops TDS
📆 Duration: 7 days
📏 Volume Example:
14 × 12 = 168 mg per dose
(168 / 125) × 1.2 = ~1.61 ml per dose


đŸ§Ŧ 2nd Generation – Cefaclor
Brand: Oticlor P/D
💉 Formulation: 125 mg / 1.2 ml
🧒 Dose: 12 mg/kg/dose — TDS
⚡ Shortcut: Weight × 2 drops = 12 × 2 = 24 drops TDS
📆 Duration: 7 days
📏 Volume Example:
12 × 12 = 144 mg per dose
(144 / 125) × 1.2 = ~1.38 ml per dose


➕ Cefuroxime + Clavulanic Acid (2nd Gen)
Brand: Clavusef Susp
💉 Formulation: 125 + 31.25 mg / 5 ml
🧒 Dose: 15 mg/kg/dose — BD (2 times/day)
⚡ Shortcut: Weight Ãˇ 1.6 = 12 Ãˇ 1.6 = ~7.5 ml BD
📆 Duration: 7 days
📏 Volume Example:
15 × 12 = 180 mg per dose
(180 / 125) × 5 = ~7.2 ml
(Note: Consider only cefuroxime part for dose calc)


đŸ§Ŧ 3rd Generation Cephalosporins

---

1ī¸âƒŖ Cefixime (Cef-3)

💊 Brand:

Cef-3 P/D (Paediatric Drops)

Cef-3 Susp (Syrup)

💉 Formulations:

P/D: 25 mg / 1 ml

Susp: 100 mg / 5 ml

🧒 Dose:

5 mg/kg/dose

BD (Twice a day)

⚡ Shortcut:

P/D: Weight × 3 drops BD

Susp: Weight Ãˇ 4 = ml BD

âŗ Duration:

7 days

Example (Child Weight = 12 kg)

---

P/D (25 mg/ml):

🧮 Calculation:
5 mg × 12 = 60 mg per dose

60 mg / 25 mg = 2.4 ml
Or use shortcut:
12 kg × 3 = 36 drops BD

💡 Final Dose:
2.4 ml or 36 drops BD

Suspension (100 mg/5 ml):

🧮 Calculation:
5 mg × 12 = 60 mg per dose

60 / 100 × 5 = 3 ml BD
Or use shortcut:
12 kg Ãˇ 4 = 3 ml BD

💡 Final Dose:
3 ml BD



đŸ§Ŧ 4th Generation – Ceftibuten
Brand: Zoventa Susp
💉 Formulation: 90 mg / 5 ml
🧒 Dose: 9 mg/kg/dose — once daily
⚡ Shortcut: Weight Ãˇ 2 → 12 Ãˇ 2 = 6 ml once daily
📆 Duration: 7 days
📏 Volume Example:
9 × 12 = 108 mg per dose
(108 / 90) × 5 = ~6 ml once daily


B. Fluoroquinolones – Sharp Shooter!
đŸŽ¯đŸ§Ē
Ciprofloxacin (Ciprocin Susp)
đŸ’Ĩ🧃 Formulation: 250 mg / 5 ml
â€ĸ āĻĄā§‹āϜ: 12.5 mg/kg BD
â€ĸ Shortcut: Wt Ãˇ 4 ml BD
â€ĸ ✅ ⧧⧍ āϕ⧇āϜāĻŋ → ā§Š ml āϏāĻ•āĻžāϞ⧇ āĻ“ āϰāĻžāϤ⧇


C. Macrolides – āĻ āĻžāĻ¨ā§āĻĄāĻž-āĻ•āĻžāĻļāĻŋāϰ expert
đŸ—ŖđŸ¤§đŸŒŦ
Azithromycin (Rozith Susp)
🌈đŸ“ĻđŸŒŋđŸŽ¯ Formulation: 200 mg / 5 ml
â€ĸ āĻĄā§‹āϜ: 10 mg/kg OD
â€ĸ Shortcut: Wt Ãˇ 4 ml OD
â€ĸ ✅ ⧧⧍ āϕ⧇āϜāĻŋ → ā§Š ml āĻĻāĻŋāύ⧇ āĻāĻ•āĻŦāĻžāϰ, ā§Ģ āĻĻāĻŋāύ


Clarithromycin (Klarix Susp)
đŸŒŋđŸŽ¯ Formulation: 125 mg / 5 ml
â€ĸ āĻĄā§‹āϜ: 7.5 mg/kg BD
â€ĸ Shortcut: Wt Ãˇ 3.3 ml BD
â€ĸ ✅ ⧧⧍ āϕ⧇āϜāĻŋ → ā§Š.ā§Ŧ ml āĻĻāĻŋāύ⧇ ⧍ āĻŦāĻžāϰ


Erythromycin (Eromycin)
🔴💧 Formulation:
â€ĸ P/D: 50 mg/1.25 ml
â€ĸ Susp: 125 mg / 5 ml
â€ĸ āĻĄā§‹āϜ: 15 mg/kg TDS
â€ĸ Shortcut: Wt × 5 drops TDS
â€ĸ Shortcut:WtÃˇ1.6
â€ĸ ✅ ⧧⧍ āϕ⧇āϜāĻŋ → ā§Ŧā§Ļ āĻĄā§āϰāĻĒ āĻĻāĻŋāύ⧇ ā§Š āĻŦāĻžāϰ


D. Penicillin – āĻĒ⧁āϰāĻžāϤāύ āĻ•āĻŋāĻ¨ā§āϤ⧁ āĻ—ā§‹āĻ˛ā§āĻĄā§‡āύ āĻ“āώ⧁āϧ
🏆đŸĻ đŸ›Ą
Amoxicillin + Clavulanic (Clacido)
Formulation: 125 + 31.25 mg / 5 ml
â€ĸ āĻĄā§‹āϜ: 15 mg/kg TDS
â€ĸ Shortcut: Wt Ãˇ 1.6 ml
â€ĸ ✅ ⧧⧍ āϕ⧇āϜāĻŋ → ā§­.ā§Ģ ml āĻĻāĻŋāύ⧇ ā§Š āĻŦāĻžāϰ



Flucloxacillin (Fluclox Susp)
đŸĻ đŸ”Ĩ Formulation: 125 mg / 5 ml
â€ĸ āĻĄā§‹āϜ: 18 mg/kg/dose
â€ĸ Shortcut: Wt Ãˇ 1.4 ml TDS
â€ĸ ✅ ⧧⧍ āϕ⧇āϜāĻŋ → ā§Ž.ā§Ģ ml āĻĻāĻŋāύ⧇ ā§Š āĻŦāĻžāϰ


Phenoxymethyl Penicillin (Penvik Forte)
đŸĻˇđŸŽ¯ Formulation: 250 mg / 5 ml
â€ĸ āĻĄā§‹āϜ: 25 mg/kg BD
â€ĸ Shortcut: Wt Ãˇ 2 ml BD
â€ĸ ✅ ⧧⧍ āϕ⧇āϜāĻŋ → ā§Ŧ ml āĻĻāĻŋāύ⧇ ⧍ āĻŦāĻžāϰ
â€ĸ āϏāĻŽāϝāĻŧāĻ•āĻžāϞ: ā§­â€“ā§§ā§Ē āĻĻāĻŋāύ



Nitrofurantoin (Nintoin)
đŸšŊđŸĻ  Formulation: 25 mg / 5 ml
â€ĸ āĻĄā§‹āϜ: 2 mg/kg TDS
â€ĸ Shortcut: Wt Ãˇ 2.5 ml
â€ĸ ✅ ⧧⧍ āϕ⧇āϜāĻŋ → ā§Ē.ā§Ž ml āĻĻāĻŋāύ⧇ ā§Š āĻŦāĻžāϰ

let me know if there are any errors.

09/05/2025



(Tab Scabo 6 mg & 12 mg)

āĻŦāĻžāĻšā§āϚāĻžāĻĻ⧇āϰ Dose_āĻĒā§āϰāϤāĻŋ ā§Ģ āϕ⧇āϜāĻŋāϰ āϜāĻ¨ā§āϝ 1 mg

👉15 Kg āĻšāϞ⧇ 3 Mg āĻĒāĻžāĻŦ⧇āĨ¤ āϤāĻžāĻšāϞ⧇ Tab Scabo 6 mg (āĻ…āĻ°ā§āϧ⧇āĻ•)

đŸ‘‰ā§¨ā§Ģ-ā§Šā§Ļāϕ⧇āϜāĻŋ āĻšāϞ⧇ 6 mg ( Tab Scabo 6 mg)

👉60 āϕ⧇āϜāĻŋ āĻšāϞ⧇ 12 mg (Tab Scabo 12 mg)

50āϕ⧇āϜāĻŋ āĻāϰ āĻŦ⧇āĻļāĻŋ āĻšāϞ⧇āĻ“ 12mg āĻĻā§‡ā§ŸāĻž āϝāĻžāĻŦ⧇āĨ¤
________________
â€ĸ 15 kg āĻāϰ āĻ•āĻŽ āĻšāϞ⧇ Contraindicated
â€ĸ Pregnancy āϤ⧇ Contraindicated
â€ĸ 2 āĻŦāĻ›āϰ⧇āϰ āύāĻŋāĻšā§‡ Recommended āύ⧟
â€ĸ Avoid in lactating mother
â€ĸ Taking On Empty Stomach
â€ĸ Ivermectin could reduce malaria incidence (31–71%) at the community level

âšĄī¸

05/05/2025

Must to know
💠 Fever + foul smelling cough + clubbing:
➤ Lung abscess
➤ Bronchiectasis

💠 Clubbing + Crepitation:
➤ Bronchiectasis
➤ Interstitial lung disease

📌 āϝāĻĻāĻŋ āϰ⧋āĻ—āĻŋ āĻ•āĻžāĻļāĻŋ āĻĻā§‡ā§ŸāĻžāϰ āĻĒāϰ crepitation āĻ•āĻŽā§‡ āϝāĻžā§Ÿ āĻŦāĻž āϚāϞ⧇ āϝāĻžā§Ÿ āϤāĻžāĻšāϞ⧇ Bronchiectasis

📌 āϝāĻĻāĻŋ āϰ⧋āĻ—āĻŋ āĻ•āĻžāĻļāĻŋ āĻĻā§‡ā§ŸāĻžāϰ āĻĒāϰāĻ“ crepitation āĻŦāĻŋāĻĻā§āϝāĻŽāĻžāύ āĻĨāĻžāϕ⧇ āϤāĻžāĻšāϞ⧇ ILD

Psoriasis đŸ”Ŧ Psoriasis āĻšāϞ⧋ āĻāĻ•āϟāĻŋ chronic, non-contagious, immune-mediated inflammatory skin disease. āĻ¤ā§āĻŦāϕ⧇ āĻĻā§āϰ⧁āϤ āϕ⧋āώ āĻŦāĻŋāĻ­āĻžāϜ...
04/05/2025

Psoriasis
đŸ”Ŧ Psoriasis āĻšāϞ⧋ āĻāĻ•āϟāĻŋ chronic, non-contagious, immune-mediated inflammatory skin disease.
āĻ¤ā§āĻŦāϕ⧇ āĻĻā§āϰ⧁āϤ āϕ⧋āώ āĻŦāĻŋāĻ­āĻžāϜāύ⧇āϰ āĻ•āĻžāϰāϪ⧇ rash with itchy, scaly patches, most commonly on the knees, elbows, trunk and scalp.

📌 Etiology:
Exact cause āĻ…āϜāĻžāύāĻž, āϤāĻŦ⧇ āĻāϟāĻŋ āĻāĻ•āϟāĻŋ multifactorial disorderāĨ¤
Genetic predisposition + Environmental trigger = Disease onset
Common triggers: āχāύāĻĢ⧇āĻ•āĻļāύ, āĻ¸ā§āĻŸā§āϰ⧇āϏ, āĻ¸ā§āĻ•āĻŋāύ āχāύāϜ⧁āϰāĻŋ (Koebner phenomenon), āĻ•āĻŋāϛ⧁ āĻ“āώ⧁āϧ (beta-blockers, lithium, antimalarials)

đŸ§Ŧ Pathophysiology:
T-cell mediated immune response āĻ¤ā§āĻŦāϕ⧇āϰ āϕ⧇āϰāĻžāϟāĻŋāύ⧋āϏāĻžāχāϟāϕ⧇ āĻšāĻžāχāĻĒāĻžāϰāĻĒā§āϰ⧋āϞāĻŋāĻĢāĻžāϰ⧇āĻļāύ⧇ āĻŦāĻžāĻ§ā§āϝ āĻ•āϰ⧇āĨ¤
āĻāϤ⧇ ā§Š-ā§Ģ āĻĻāĻŋāύ⧇āχ āĻ¤ā§āĻŦāϕ⧇āϰ āϕ⧋āώ āĻ¸ā§āĻ•āĻŋāύ āϏāĻžāϰāĻĢ⧇āϏ⧇ āĻĒ⧌āρāϛ⧇ āϝāĻžāϝāĻŧ (āĻ¸ā§āĻŦāĻžāĻ­āĻžāĻŦāĻŋāĻ• ā§¨ā§Ž āĻĻāĻŋāύ⧇āϰ āĻŦāĻĻāϞ⧇)āĨ¤

🔍 Clinical Features:
Well-demarcated erythematous plaques with silvery scales
Common sites: scalp, elbows, knees, sacral area
Auspitz sign: scale āϤ⧁āϞ⧇ āĻĢ⧇āϞāϞ⧇ āύāĻŋāĻšā§‡ pinpoint bleeding
Koebner phenomenon: āχāύāϜ⧁āϰāĻŋ āĻŦāĻž āĻ¸ā§āĻ•ā§āĻ°ā§āϝāĻžāĻšā§‡ āύāϤ⧁āύ āϞ⧇āĻļāύ āĻĻ⧇āĻ–āĻž āĻĻ⧇āϝāĻŧ
Nail involvement: pitting, onycholysis, oil-drop sign

🧠 Types of Psoriasis:
Plaque psoriasis (vulgaris) – āϏāĻŦāĻšā§‡ā§Ÿā§‡ āϏāĻžāϧāĻžāϰāĻŖ (~80%)
Guttate psoriasis – āϛ⧋āϟ āϛ⧋āϟ papule, āĻŦ⧇āĻļāĻŋ āĻĻ⧇āĻ–āĻž āϝāĻžāϝāĻŧ streptococcal throat infection āĻāϰ āĻĒāϰ⧇
Pustular psoriasis – sterile pustules, painful
Erythrodermic psoriasis – rare but life-threatening
Inverse psoriasis – flexural areas (e.g. axilla, groin)

đŸ§Ē Diagnosis:
Clinical – typical lesion āĻĻ⧇āϖ⧇
Skin biopsy (if needed): shows Munro microabscess, parakeratosis, elongated rete ridges

💊 Treatment Overview:
Topical agents: Corticosteroids, Calcipotriol (Vitamin D analog), Coal tar
Phototherapy: UVB or PUVA
Systemic agents: Methotrexate, Cyclosporine, Acitretin
Biologics: TNF-alpha inhibitors (e.g. Etanercept), IL-17/IL-23 inhibitors
🔄 Psoriasis āĻāĻŦāĻ‚ psoriatic arthritis āĻāĻ•āϏāĻžāĻĨ⧇ āĻšāϤ⧇ āĻĒāĻžāϰ⧇ (~30%)āĨ¤
Thank you

16/03/2025


AKI 🆚 CKD

āĻ•āĻžāϰ⧋ Creatinine āĻŦ⧇āĻļāĻŋ āĻĒ⧇āϞ⧇ āφāĻŽāϰāĻž āĻ•āĻŋāĻ­āĻžāĻŦ⧇; āĻŦ⧁āϜāĻŦā§‹- is it AKI or CKD!! Creatinine āϤ⧋ AKI āĻ“ āĻŦāĻžā§œā§‡ āφāĻŦāĻžāϰ CKD āϤ⧇āĻ“ āĻŦāĻžā§œā§‡āĨ¤đŸ˜ĸđŸ˜ĸ(āĻāĻĻ⧇āϰ āĻŽāĻ§ā§āϝ⧇ āĻ•āĻŋāϛ⧁ Hallmark features āĻšāϞ⧋)

📌 In case of AKI

â€ĸ Onset within Days to Weeks!
â€ĸ BP (Hypotension)
â€ĸ Nrmally Anemia āĻĨāĻžāϕ⧇ āύāĻž
â€ĸ Kidney āĻāϰ Size Normal āĻĨāĻžāϕ⧇
â€ĸ Renal Osteodystrophy āĻĨāĻžāϕ⧇ āύāĻž
â€ĸ Oligoria/Anuria-Drug history

📌 In Case of CKD ( Long History)

â€ĸ Anaemia ( Severe)**
â€ĸ Bilateral Small Kidney***(Except DM)
â€ĸ Renal Osteodystrophy ***
â€ĸ Hypertension āĻĨāĻžāĻ•āĻŦ⧇(Cardiomyopathy)

āĻāĻ›āĻžā§œāĻžāĻ“ S. calcium, Phosphate,Vit-D & PTH āĻāϰ abnormalities āĻĨāĻžāĻ•āĻŦ⧇ āϝ⧇āĻŽāύ--Low calcium,Low Vit-D, High Phosphate,High PTH....

DM āĻĨ⧇āϕ⧇ āϝāĻ–āύ CKD āĻšāϞ⧇ Kidney size normal āĻĨāĻžāϕ⧇āĨ¤āφāϰ ADPKD or Chroric Obstructive uropathy āĻĨ⧇āϕ⧇ āĻšāϞ⧇ Kidney Size āĻŦ⧜ āĻĨāĻžāϕ⧇āĨ¤

āĻāĻ­āĻžāĻŦ Creatinine āĻŦ⧇āĻļāĻŋ āĻĒ⧇āϞ⧇ AKI &CKD āφāϞāĻžāĻĻāĻž āĻ•āϰāϤ⧇ āĻĒāĻžāϰāĻŋ!!!!!!!

16/02/2025

āĻĢ⧇āϏāĻŦ⧁āϕ⧇ āĻ…āύ⧇āĻ• āĻĢā§āϰ⧇āĻ¨ā§āĻĄ āχāύāĻŦāĻ•ā§āϏ⧇ āĻŦāϞ⧇ āĻ āĻžāĻ¨ā§āĻĄāĻž āϞāĻžāĻ—āϛ⧇ āĻŽā§‹āύāĻžāϏ ā§§ā§Ļ āϖ⧇āϝāĻŧ⧇āϛ⧇ āφāϰ āĻ•āĻŋ āĻ–āĻžāĻŦ⧇? āϜāĻŋāĻœā§āĻžā§‡āϏ āĻ•āϰāĻŋ āĻŽā§‹āύāĻžāϏ āϕ⧇āύ ? āωāĻ¤ā§āϤāϰ āφāϏ⧇ āĻ āĻžāĻ¨ā§āĻĄāĻžāϤ⧇ āĻāĻ•āĻŦāĻžāϰ āĻĄāĻžāĻ•ā§āϤāĻžāϰ āϖ⧇āϤ⧇ āĻĻāĻŋāϝāĻŧ⧇āϛ⧇āύ āϤāĻžāϰāĻĒāϰ āĻĨ⧇āϕ⧇ āĻ āĻžāĻ¨ā§āĻĄāĻž āϞāĻžāĻ—āϞ⧇ āĻāϟāĻž āĻ–āĻžāϝāĻŧ.. āĻāϟāĻž āĻ›āĻžāĻĄāĻŧāĻž āύāĻžāĻ•āĻŋ āϤāĻžāϰ āĻ­āĻžāϞ⧋ āĻšāϝāĻŧ āύāĻžāĨ¤ 😑😑

Stop irrational use of monteleukast....
āĻŽāĻŋāϏ⧇āϏ āĻāĻ•ā§āϏ āĻŦ⧟āϏ 55 āĻŦāĻ›āϰ, āĻšāĻžāχāĻĒāĻžāϰāĻŸā§‡āύāĻļāύ āĻ“ āĻĄāĻžā§ŸāĻžāĻŦ⧇āϟāĻŋāϏ āĻāϰ āϰ⧋āĻ—ā§€āĨ¤ āύāĻŋ⧟āĻŽāĻŋāϤ āĻĒā§āϰ⧇āϏāĻžāϰ āĻ“ āĻĄāĻžā§ŸāĻžāĻŦ⧇āϟāĻŋāϏ āĻāϰ āĻ”āώāϧ āĻ–āĻžāύāĨ¤ āĻĒā§āϰ⧇āϏāĻžāϰ āĻ“ āĻĄāĻžā§ŸāĻžāĻŦ⧇āϟāĻŋāϏ āĻĻ⧁āĻŸā§‹āχ āĻ•āĻ¨ā§āĻŸā§āϰ⧋āϞ āĻ āφāϛ⧇āĨ¤ āϰ⧋āĻ—ā§€āϰ āύāĻŋāĻœā§‡āϰ āϕ⧋āύ āϏāĻŽāĻ¸ā§āϝāĻž āύ⧇āχ, āĻ•āĻŋāĻ¨ā§āϤ⧁ āωāύāĻžāϰ āĻŦāĻžāϏāĻžāϰ āϞ⧋āĻ•āϜāύ āωāύāĻžāϕ⧇ āύāĻŋā§Ÿā§‡ āφāϏāϛ⧇āύāĨ¤ āωāύāĻžāϰ āĻŽā§‡ā§Ÿā§‡ āϜāĻžāύāĻžāύ- āĻ—āϤ 5 āĻŽāĻžāϏ āĻĨ⧇āϕ⧇ āωāύāĻžāϰ āĻŽāĻ§ā§āϝ⧇ āĻāĻ•āϟāĻž āĻĒāϰāĻŋāĻŦāĻ°ā§āϤāύ āϞāĻ•ā§āĻˇā§āϝ āĻ•āϰāϛ⧇āύ, āωāύāĻŋ āĻ•āĻžāϰ⧋ āϏāĻžāĻĨ⧇ āĻ•āĻĨāĻž āĻŦāϞ⧇āύ āύāĻž, āĻļ⧁āϧ⧁ āϕ⧇āω āĻ•āĻŋāϛ⧁ āĻŦāϞāϞ⧇ āωāĻ¤ā§āϤāϰ āĻĻ⧇āύ, āϏāĻŦ āϏāĻŽā§Ÿ āϚ⧁āĻĒāϚāĻžāĻĒ āĻĨāĻžāϕ⧇āύ, āĻŦāĻžāϏāĻžā§Ÿ āϕ⧋āύ āφāĻ¤ā§āĻ¨ā§€ā§Ÿ āĻāĻŽāύāĻ•āĻŋ āωāύāĻžāϰ āĻŦā§‹āύ āĻŦāĻžāϏāĻžā§Ÿ āφāϏāϞ⧇āĻ“ āĻŦāϏāϤ⧇ āĻŦāϞ⧇āύ āύāĻž, āϖ⧇āϤ⧇ āĻŦāϞ⧇āύ āύāĻž āχāĻ¤ā§āϝāĻžāĻĻāĻŋāĨ¤
āωāύāĻžāϰāĻž āχāϤāĻŋāĻŽāĻ§ā§āϝ⧇ āĻ•ā§Ÿā§‡āĻ• āϜāĻžā§ŸāĻ—āĻžā§Ÿ āĻ•āύāϏāĻžāϞāĻŸā§‡āĻļāύ āύāĻŋā§Ÿā§‡āϛ⧇āύāĨ¤ āĻ•āĻŋāĻ¨ā§āϤ⧁ āϕ⧋āύ āĻšā§‡āĻžā§āϜ āύ⧇āχāĨ¤

āφāĻŽāĻŋ āωāύāĻžāϕ⧇ āϜāĻŋāĻœā§āĻžāĻžāϏāĻž āĻ•āϰāϞāĻžāĻŽ āĻ•āĻŋ āĻ…āϏ⧁āĻŦāĻŋāϧāĻž, āωāύāĻžāϰ āωāĻ¤ā§āϤāϰ āϕ⧋āύ āϏāĻŽāĻ¸ā§āϝāĻž āύ⧇āχāĨ¤ āĻ•ā§āϞāĻŋāύāĻŋāĻ•ā§āϝāĻžāϞ āĻāĻ•ā§āϏāĻžāĻŽ āĻ āϏāĻŦ āĻ•āĻŋāϛ⧁ āύāϰāĻŽāĻžāϞāĨ¤ āϤāĻŦ⧇ āωāύāĻžāϰ āĻĢ⧇āϏ āĻĻ⧇āϖ⧇ āĻŽāύ⧇ āĻšā§Ÿ āϟāĻŋāĻĒāĻŋāĻ•ā§āϝāĻžāϞ āĻĄāĻŋāĻĒā§āϰ⧇āϏāĻĄ āĻĢ⧇āϏāĨ¤ āφāĻŽāĻŋ āϰ⧁āϟāĻŋāύ āĻŸā§‡āĻ¸ā§āϟ, FBS, 2ABF, āĻĨāĻžāχāĻ°ā§Ÿā§‡āĻĄ āĻŸā§‡āĻ¸ā§āϟ āĻ•āϰāϤ⧇ āĻĻāĻŋāϞāĻžāĻŽāĨ¤

āϏāĻŦ āϰāĻŋāĻĒā§‹āĻ°ā§āϟ āύāϰāĻŽāĻžāϞāĨ¤ āĻāĻŦāĻžāϰ āφāĻŽāĻŋ āϰ⧋āĻ—ā§€āϰ āϏāĻžāĻĨ⧇ āĻāĻ•āĻž āĻ•āĻĨāĻž āĻŦāϞāϤ⧇ āϚāĻžāχāϞāĻžāĻŽāĨ¤ āϰ⧋āĻ—ā§€āϰ āĻāĻ• āϛ⧇āϞ⧇ āĻ“ āĻāĻ• āĻŽā§‡ā§Ÿā§‡ āĻ­āĻžāĻ°ā§āϏāĻŋāϟāĻŋāϤ⧇ āĻĒā§œā§‡āĨ¤ āϰ⧋āĻ—ā§€āϰ āϏāĻžāĻĨ⧇ āĻāĻ•āĻžāĻ¨ā§āϤ āĻ•āĻĨāĻž āĻŦāϞāĻžā§Ÿ āϕ⧋āύ āϧāϰāύ⧇āϰ āĻŦā§āϝāĻ•ā§āϤāĻŋāĻ—āϤ, āĻĒāĻžāϰāĻŋāĻŦāĻžāϰāĻŋāĻ•, āϏāĻžāĻŽāĻžāϜāĻŋāĻ• āĻ•āύāĻĢā§āϞāĻŋāĻ•ā§āϟ āύ⧇āχāĨ¤

āφāĻŽāĻŋ āϰ⧋āĻ—ā§€āϰ āĻŽā§‡ā§Ÿā§‡āϕ⧇ āĻĄā§‡āϕ⧇ āωāύāĻžāϰ āϏāĻžāĻ°ā§āĻŦāĻŋāĻ• āĻ…āĻŦāĻ¸ā§āĻĨāĻž āϜāĻžāύāĻžāϞāĻžāĻŽ- āϰ⧋āĻ—ā§€ āĻĄāĻŋāĻĒā§āϰ⧇āĻļāύ⧇ āϭ⧁āĻ—āϛ⧇āύ, āĻ•āĻŋāĻ¨ā§āϤ⧁ āĻĄāĻŋāĻĒā§āϰ⧇āĻļāύ⧇āϰ āϕ⧋āύ āĻ•āĻžāϰāύ āĻĒāĻžāĻ“ā§ŸāĻž āϝāĻžāĻšā§āϛ⧇ āύāĻžāĨ¤ āφāĻŽāĻŋ āĻŦāϞāϞāĻžāĻŽ āĻšā§ŸāϤ āωāύāĻžāϰ āĻŽā§‡ā§Ÿā§‡ āĻŦ⧜ āĻšāĻšā§āϛ⧇ āϤāĻžāϰ āĻŦāĻŋā§Ÿā§‡ āύāĻŋā§Ÿā§‡ āωāύāĻŋ āϚāĻŋāĻ¨ā§āϤāĻŋāϤ āĻĨāĻžāϕ⧇āύ, āĻŸā§‡āύāĻļāύ āĻ•āϰ⧇āύ āχāĻ¤ā§āϝāĻžāĻĻāĻŋāĨ¤

āĻāĻŦāĻžāϰ āϰ⧋āĻ—ā§€āϰ āĻŽā§‡ā§Ÿā§‡ āϜāĻžāύāĻžāϞ āϝ⧇ āϰ⧋āĻ—ā§€ āĻŦāĻŋāĻ—āϤ 5 āĻŦāĻ›āϰ āϧāϰ⧇ Monteleukast āĻ–āĻžāύ, āĻāĻ•āϜāύ āĻĄāĻžāĻ•ā§āϤāĻžāϰ āĻāϟāĻŋ āĻŦāĻ¨ā§āϧ āĻ•āϰ⧇ āĻĻ⧇āύāĨ¤ āĻāϰāĻĒāϰ āĻāĻ•āĻĻāĻŋāύ āωāύāĻŋ āĻāϏāĻŋ āĻ›ā§‡ā§œā§‡ āϰ⧇āĻ¸ā§āϟ āύāĻŋāĻšā§āĻ›āĻŋāϞ⧇āύ, āϏ⧇āχ āϏāĻŽā§Ÿ āωāύāĻžāϰ āĻĻāĻŽ āĻŦāĻ¨ā§āϧ āĻšā§Ÿā§‡ āφāϏ⧇āĨ¤ āωāύāĻŋ āĻŽāύ⧇ āĻ•āϰ⧇āύ āϕ⧇ monteleukast āĻŦāĻ¨ā§āϧ āĻ•āϰāĻžāϰ āĻ•āĻžāϰāύ⧇ āĻāĻŽāύ āĻšā§Ÿ, āωāύāĻŋ āφāĻŦāĻžāϰāĻ“ āĻāϟāĻŋ āĻ–āĻžāĻ“ā§ŸāĻž āĻļ⧁āϰ⧁ āĻ•āϰ⧇āύāĨ¤ āĻāϰāĻĒāϰ āĻĨ⧇āϕ⧇āχ āϤāĻžāϰ āϏāĻŽāĻ¸ā§āϝāĻžāϗ⧁āϞ⧋ āĻļ⧁āϰ⧁ āĻšā§ŸāĨ¤

Monteleukast āĻāϰ āϜāĻ¨ā§āϝ FDA black box warning āĻĻāĻŋā§Ÿā§‡āϛ⧇ āϝ⧇ āĻāϟāĻŋ āĻŦā§āϝāĻŦāĻšāĻžāϰ⧇āϰ āĻĒāϰ āϰ⧋āĻ—ā§€āϰ suicidal thought, agitation, anxiety, depression, behavioral change āĻšāϤ⧇ āĻĒāĻžāϰ⧇āĨ¤ āĻāχāϜāĻ¨ā§āϝ āϝāĻžāĻĻ⧇āϰāϕ⧇ monteleukast āĻĻā§‡ā§ŸāĻž āĻšāĻŦ⧇ āϤāĻžāĻĻ⧇āϰāϕ⧇ āĻāϗ⧁āϞ⧋ āĻŽāύāĻŋāϟāϰ āĻ•āϰāϤ⧇ āĻšāĻŦ⧇āĨ¤ āϕ⧋āύ āϧāϰāύ⧇āϰ āĻšā§‡āĻžā§āϜ āĻĒ⧇āϞ⧇ āĻŦāĻ¨ā§āϧ āĻ•āϰ⧇ āĻĻāĻŋāϤ⧇ āĻšāĻŦ⧇āĨ¤

Take home message:
1. Use monteleukast only if it is absolutely indicated. Indications are asthma (as preventer), allergic rhinitis, allergic dermatitis.
2. Monitor the patient for any change of behavior and stop immediately if any.

14/01/2025

01

1.... Antibiotics-: āϏāĻŦ Penicillin & cephalosporin are Safe in pregnancy (Amoxicillin,Flucloxacillin,Cefafroxil,cephradine, Cefuroxime, cefixim, Ceftriaxone etc...)

Uti In pregnancy 1st & 2nd trimester DOC (Nitrofurantoin) Term(Cefuroxim)

2.... Antihistamines-: Cholpheniramine(Tab Sinamin), Cetrizine(Alatrol), Levocetrizine (Alcet)

3..... Vomiting āĻāϰ āϜāĻ¨ā§āϝ - Tab Acliz plus, Ondansatron ( Tab Emistat) , Palonsetron( Tab paloxi)

4.... Anti-hypertensive (Labetalol, Alfa methyl Dopa,Nifedipin)

5...Safest fr Pain -- Paracetamol

7.. Scabies āĻāϰāϜāĻ¨ā§āϝ Permethrin (Cream Perosa)

8... Tinea āĻāϰ āϜāĻ¨â€ā§āϝ āϏāĻŦ Topical Antifungal āĻĒā§āϰ⧇āĻ—ā§āĻ¨ā§āϝāĻžāϏāĻŋ Safe! oral Terbinafin Also safe!!

9.... āϏāĻŦ Topical Steroid āĻĒā§āϰ⧇āĻ—āĻ¨ā§āϝāĻžāĻ¨ā§āϏāĻŋ Safe

10... All anti asthmatic Drug are āĻĒā§āϰ⧇āĻ—āĻ¨ā§āϝāĻžāĻ¨ā§āϏāĻŋ āϏ⧇āχāĻĢāĨ¤prednisolone , Montelucast

12... 11... Skin Infection - Topical Antibiotic Mupirocin( Oint Trego) safe

12....Abdominal pain- Tiemonium( Tab Algin ) āĻĒā§āϰ⧇āĻ—āĻ¨ā§āϝāĻžāĻ¨ā§āϏāĻŋ Safe!

13....Constipation in āĻĒā§āϰ⧇āĻ—āĻ¨ā§āϝāĻžāĻ¨ā§āϏāĻŋ- Milk of Magnesia, Lactulose( Syp Avolac),āχāϏāĻŦāϗ⧁āϞ,

14....āϏāĻŦ PPI Safe--avoid Omeprazol

16... Cough Expectorants -- Syp Mucolyt āĻĒā§āϰ⧇āĻ—ā§āĻ¨ā§āϝāĻžāϏāĻŋ Safe!

17....UTI in āĻĒā§āϰ⧇āĻ—āĻ¨ā§āϝāĻžāĻ¨ā§āϏāĻŋ-- Nitrofurantoin, Cefuroxime

18...Calcium, Folic Acid, Iron āĻĒā§āϰ⧇āĻ—ā§āĻ¨ā§āϝāĻžāϏāĻŋ Safe!

19...Momvit multivitamin, Vit-C, ViT-D,Vit B complex --āĻĒā§āϰ⧇āĻ—ā§āĻ¨ā§āϝāĻžāϏāĻŋ Safe

20...Migrane-- Paracetamol

21...Antidiabetic -- Best choice Insulin

22...Permethrin shamooo Safe for lice in pg

23.... Antiviral Acyclovir ( Tab Virux) safe in Pg

24...Oral thrush in pG -- Nystatin, Miconazole

25... For Scabies-- Cream Permethrin ( Perosa)
āϚāϞāĻŦ⧇_______

13/01/2025

Blockers in Diabetic āĻĒ⧇āĻļ⧇āĻ¨ā§āϟ,Specially āϝ⧇āχ Diabetic āĻĄā§āϰāĻžāĻ— āϗ⧁āϞ⧋ Hypoglycaemia āĻ•āϰāϤ⧇ āĻĒāĻžāϰ⧇(āϝ⧇āĻŽāύ-Sulphonylurea,Insulin) --āĻāϤ⧇ āĻ•āϰ⧇ āĻāϰāĻž Hypoglycaemia āĻšāϞ⧇āĻ“ āĻŦ⧁āϜāϤ⧇ āĻĒāĻžāϰāĻŦ⧇ āύāĻžāĨ¤

āĻ•āĻžāϰāĻŖ Beta blockers āϗ⧁āϞ⧋ Hypoglycaemia āĻāϰ Symptoms (āϝ⧇āĻŽāύ Tachycardia) masking āĻ•āϰ⧇ āϰāĻžāϖ⧇ ( Hide āĻ•āϰ⧇ āϰāĻžāϖ⧇) & Even Decrease serum glucose levels..āĨ¤āĻāϤ⧇ āĻĒ⧇āĻļ⧇āĻ¨ā§āϟ hypoglycaemia āĻšāϞ⧇āĻ“ āĻŦ⧁āϜāϤ⧇ āĻĒāĻžāϰāĻŦ⧇ āύāĻžāĨ¤āĻāϟāĻžāϕ⧇āχ āĻŦāϞāĻž āĻšā§Ÿ Masking of hypoglycaemia-

Also Avoid Beta-blockr in young male!!!

âšĄī¸

Address

International Medical College
Rajshahi

Website

Alerts

Be the first to know and let us send you an email when Dr-Anik Maitra posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Share

Category